4T1 Metastatic Tumor Model Service for Breast Cancer

The 4T1 Metastatic Tumor Model Service for Breast Cancer provides the most widely validated immunocompetent platform for studying spontaneous, multi-organ dissemination of triple-negative mammary carcinoma. Alfa Cytology offers this model as a turnkey preclinical solution — authenticated 4T1 cell preparation, BALB/c mouse implantation by subcutaneous or orthotopic routes, longitudinal tumor and metastasis tracking, and comprehensive endpoint characterization — enabling breast cancer programs to generate decision-grade data in an intact immune context.

Overview of 4T1 Metastatic Tumor Model for Breast Cancer

4T1 is a murine mammary carcinoma cell line originally isolated by Fred Miller and colleagues at the Karmanos Cancer Institute as one of several clonal derivatives of the 410.4 tumor, itself arising spontaneously in an MMTV-positive BALB/c mouse foster-nursed on a C3H mother. The line was selected without mutagen treatment for resistance to 6-thioguanine, a property that later proved uniquely powerful: metastatic cells — even single cells — can be recovered from distant organs by selective plating on 6-thioguanine medium, giving the model a quantitative metastasis readout unavailable in most tumor systems. Molecularly, 4T1 displays a basal-like, triple-negative phenotype (ER⁻/PR⁻/HER2⁻) and expresses high levels of vimentin, CXCL1, CXCL2, and VEGF, faithfully mirroring the biology of human advanced breast cancer.

Fig 1. Cell-centric characterization of 4T1 breast cancer cells with PD-L1 overexpression: time-dependent proliferation, Transwell migration and invasion assays, wound-healing closure at 0 and 12 h, and rescue experiments with anti-PD-L1 neutralizing antibody, defining the baseline phenotype for PD-L1-focused studies in the 4T1 syngeneic model. (Park, A. Young, et al., 2025)

Following implantation into syngeneic, immunocompetent BALB/c mice, 4T1 cells form aggressive primary tumors with take rates exceeding 95% and, crucially, metastasize spontaneously while the primary tumor remains in situ — first to lung and lymph nodes, then to liver, bone, brain, and other organs over a three-to-six-week window. This natural history, closely paralleling stage IV human disease, has made 4T1 the benchmark syngeneic model for dissecting the metastatic cascade in vivo, validating the pre-metastatic niche concept, and testing chemotherapy, targeted agents, and immunotherapies — including checkpoint blockade, cancer vaccines, and adoptive cell therapies — against a strongly immunosuppressive microenvironment rich in MDSCs, tumor-associated macrophages, and regulatory T cells. Firefly luciferase derivatives (4T1-Luc, 4T1-12B, 4T1-Luc2-RFP) extend the platform with non-invasive, whole-body imaging of primary growth and micrometastatic spread in vivo, while sibling lines of graded metastatic potential — non-metastatic 67NR, lymph-node-restricted 168FARN, and lung-colonizing 66cl4 — provide matched controls for mechanistic comparisons.

Cell Line Information: 4T1

4T1 is a reference murine breast cancer line whose growth and metastatic behavior in BALB/c mice closely reproduce the clinical course of advanced human breast cancer. Its defining characteristics are summarized below.

Our Services

Alfa Cytology operates the 4T1 model with dedicated infrastructure: authenticated, mycoplasma-free cell stocks kept at controlled passage, purpose-managed BALB/c colonies, and imaging-equipped suites for luciferase-based longitudinal studies. From classic subcutaneous efficacy arms to orthotopic and spontaneous-metastasis designs with organ-level endpoint analysis, each configuration is executed under rigorous randomization and quality control, then reported with clear statistical interpretation.

Workflow of 4T1 Metastatic Tumor Model Construction

Establishing a 4T1 metastatic study follows a staged process refined by decades of use, balancing rapid model development with rigorous metastasis quantification. The principal stages are outlined below:

1. Cell Line Preparation: 4T1 cells are authenticated, confirmed mycoplasma-free, and expanded at low passage; luciferase-tagged stocks are verified for reporter stability before use.
2. Mouse Acclimatization and Allocation: Female BALB/c mice (typically 6–12 weeks old) are acclimatized under specific-pathogen-free conditions and randomly assigned to study groups.
3. Tumor Implantation: Cells are administered by the selected route: about 1 × 10⁶ cells subcutaneously (optionally with Matrigel) for flank models, or approximately 1 × 10⁴ cells into the mammary fat pad for orthotopic growth.
4. Primary Tumor Monitoring: Implant sites are palpated; measurable tumors generally appear within one week, after which caliper-based volume tracking and body-weight recording proceed on a fixed schedule.
5. Randomization and Treatment: Animals are re-randomized once tumors reach the target size (e.g., approximately 100 mm³), and dosing with vehicle, reference agents (chemotherapy or checkpoint inhibitors), or test articles begins.
6. In-Life Metastasis Tracking: Tumor burden, body weight, and clinical status are followed throughout; luciferase-expressing cohorts undergo serial bioluminescence imaging in vivo to visualize metastatic progression non-invasively.
7. Terminal Metastasis Analysis: At necropsy, primary tumors are excised and weighed; lungs, liver, bone, and other organs are examined for macroscopic nodules, processed for histology, and — where applicable — dissociated for 6-thioguanine clonogenic assay to enumerate micrometastatic cells.
8. Data Integration and Reporting: Tumor-growth curves, imaging signals, metastasis counts, and survival data are statistically analyzed and compiled into a final study report.

Fig 2. 4T1 Metastatic Tumor Model construction workflow.

Case Study-4T1 Metastatic Tumor Model Development

In a representative preclinical collaboration, Alfa Cytology deployed the 4T1 metastatic model for a sponsor investigating an anti-metastatic therapeutic strategy in breast cancer. The engagement included establishment of tumors in immunocompetent BALB/c mice by the route selected for the program, structured assignment of vehicle and treatment arms, scheduled monitoring of primary tumor growth and animal condition, and terminal analysis of distant-organ metastatic burden with histopathological confirmation — delivering a consolidated evidence package that informed the client’s preclinical development planning. Study formats can be oriented toward primary-tumor efficacy, spontaneous metastasis quantification, imaging-based tracking, or combination-therapy evaluation as program goals require.

Why Choose Alfa Cytology?

Alfa Cytology combines deep familiarity with this demanding, fast-moving model and the operational discipline required to keep its metastasis biology reproducible study after study. Reasons clients select our 4T1 service include:

• Extensive hands-on experience with 4T1 across subcutaneous, orthotopic, and spontaneous-metastasis formats.
• Dual metastasis readouts: macroscopic/histological organ analysis plus quantitative 6-thioguanine clonogenic assay.
• In-house luciferase reporter lines and imaging capability for longitudinal monitoring in vivo.
• Access to matched sibling lines (67NR, 168FARN, 66cl4) for mechanism-of-action comparisons.
• Stringent quality control covering cell authentication, randomization, and blinded endpoint scoring.
• Responsive project management with concise, statistically interpreted reporting on agreed timelines.

Contact Us

If your breast cancer program needs an immunocompetent model that metastasizes the way human disease does, the 4T1 specialists at Alfa Cytology are here to help. Reach out to us to scope your study, or contact us today for a tailored quotation — let’s advance your metastasis research together.

For research use only. Not intended for any clinical use.